Key result
Global mortality from non-rheumatic degenerative mitral valve disease fell ~31% from 1990 to 2019.
Why the study?
While the burden of rheumatic mitral valve disease has been well studied, little is known about the epidemiology and mortality trends of non-rheumatic degenerative mitral valve disease.
Observational
Yes
Effect estimate: net drift -1.1% (95% CI -1.17 to -1.04)
Absolute Event Rate: 117.95% vs 170.45%
While the absolute number of deaths from non-rheumatic degenerative mitral valve disease has increased globally over the past 30 years, the age-standardized mortality rate has declined, though the burden remains significant in low-sociodemographic index regions.
NRDMVD mortality trends may inform targeted screening; extends GBD epidemiology but leaves causal associations and practice changes open pending prospective data.
BACKGROUND: The global and national burden of rheumatic mitral valve disease (MVD) has been well studied and estimated before. However, little is known about non-rheumatic degenerative MVD. Therefore, this study aimed to assess the trends in non-rheumatic degenerative MVD (NRDMVD) epidemiology, with an emphasis on NRDMVD mortality, leading risk factors, and their associations with age, period, and birth cohort. METHODS: Using the data derived from the Global Burden of Disease Study 2019, including prevalence, mortality, and disability-adjusted life years, we analyzed the burden of NRDMVD and the detailed trends of NRDMVD mortality over the past 30 years in 204 countries and territories by implementing the age-period-cohort framework. RESULTS: Globally, the number of deaths due to NRDMVD increased from 5695.89 (95% uncertainty interval [UI]: 5405.19 to 5895.4) × 1000 in 1990 to 9137.79 (95% UI: 8395.68 to 9743.55) × 1000 in 2019. The all-age mortality rate increased from 106.47 (95% UI: 101.03 to 110.2) per 100,000 to 118.1 (95% UI: 108.51 to 125.93) per 100,000, whereas the age-standardized mortality rate decreased from 170.45 (95% UI: 159.61 to 176.94) per 100,000 to 117.95 (95% UI: 107.83 to 125.92) per 100,000. The estimated net drift of mortality per year was -1.1% (95% confidence interval: -1.17 to -1.04). The risk of death due to NRDMVD increased with age, reaching its peak after 85 years old globally. Despite female patients being associated with lower local drift than male patients, no significant gender differences were observed in the age effect across countries and regions for all sociodemographic index (SDI) levels, except low-SDI regions. CONCLUSIONS: We estimated the global disease prevalence of and mortality due to NRDMVD over approximately a 30-year period. The health-related burden of NRDMVD has declined worldwide; however, the condition persisted in low-SDI regions. Moreover, higher attention should be paid to female patients.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted an observational in Non-rheumatic degenerative mitral valve disease. Time period (1990-2019) vs. 1990 baseline was evaluated on Age-standardized mortality rate per 100,000 (net drift -1.1%, 95% CI -1.17 to -1.04). From 1990 to 2019, the global age-standardized mortality rate for non-rheumatic degenerative mitral valve disease decreased from 170.45 to 117.95 per 100,000 (net drift -1.1% per year).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: